To Browse through specific lists, the search terms can be prefixed with following letters:
d: for diseases m: for molecules p: for pathways c: for cell lines v: for interaction terms d: for diseases m: for molecules p: for pathways c: for cell lines v: for interaction terms
*Search for genes, compounds, disease, cell/cell lines, organ, disease, pathway, process. (E.g CDK5)
About NetPro™
NetPro™ developed at Molecular Connections, offers solutions for the pharmaceutical and life sciences industries/researchers to streamline and speed up the drug discovery process.
NetPro™ Application Areas:
Custom curation
Expert Curation & Analysis Services are scientific services that can help expedite your research programs. The key value proposition is to leverage the ability to interpret and analyze your organization's research/experimental data and correlate it with our vast Knowledge Platforms unearthing new connections to be found and novel hypotheses to be generated.
 |
|
Cambridge, MA and Bangalore, India - Indian Life Sciences Informatics Company, Molecular Connections appoints Boston based CambridgeSoft as developer, marketer and seller for its NetPro™ small molecule interactions database.
NetPro™ is the largest, most comprehensive hand-curated knowledgebase of small molecule interactions as appearing in literature. NetPro™ contains information relevant to drug interactions & metabolism, enzyme kinetics, potential therapeutic agents etc. Small molecules in NetPro™ are categorized as drugs, molecules with therapeutic potential, metabolites, physiologically available bioactive molecules, ligands, agonists, antagonists, enzyme activators, enzyme inhibitors, bio-hazardous molecules like allergens, carcinogens and toxicants. Apart from interaction details, NetPro™ also provides binding constants, kinetic parameters, pharmacokinetic, pharmacodynamic and other quantitative details.
As a part of the arrangement, CambridgeSoft will develop a chemical structure-searchable version of NetPro™ using its ChemOffice technology. The integrated product offering will add to CambridgeSoft's growing family of database offerings, as chemists will be able to seamlessly search and retrieve information on more than 85,838 interactions for small molecules as published in literature. This number will keep growing as Molecular Connections continues to update the knowledgebase.
According to Jignesh Bhate, CEO of Molecular Connections, "Scientists increasingly want both chemistry and biology information under one platform. The rich information available in NetPro™ on small molecule interactions will significantly help chemists in their compound prioritization efforts."
Michael G. Tomasic, President & CEO of CambridgeSoft adds, "CambridgeSoft customers world wide will now have access to the high quality content of NetPro™ through both web-based and in-house installations provided by CambridgeSoft. CambridgeSoft will deliver this important data using tools and interface that are familiar to the large CambridgeSoft user community and are typical of our other database offerings."
Full integration of NetPro™ into BiblioSphere PathwayEdition Genomatix Software GmbH in Munich, Germany and Bangalore, India based Molecular Connections Private Ltd. announced today that both companies entered into a strategic partnership. As a first result Molecular Connections' Database NetPro™ will be fully integrated into Genomatix biological networks and pathway knowledge base and analysis system BiblioSphere PathwayEdition (BSPE).
NetPro™ is one of the largest expert curated database of protein-protein & protein-small molecule interactions in the world and contains highly granular contextual data on nature of interaction, pathways, diseases, location, plus a wealth of pharmacokinetics information related to the interactions.
BSPE is one of the world's largest databases of biological networks created from millions of individually modeled relationships between genes, proteins, complexes, cells and tissues. A unique combination of up-to-date text mining techniques for automated knowledge extraction and hand curation from biological experts with focus on transcription factors and gene regulation were key to success of BSPE. In addition, BSPE integrates results of genome wide DNA sequence analysis with a focus on gene regulation.
"I am absolutely delighted by this partnership with Molecular Connections," says Dr. Thomas Werner, CEO/CSO of Genomatix. "By it we are able to combine the best of both worlds: large scale text mining and our expert knowledge of gene regulation with the unbeatable expert curation of Molecular Connections' expert scientists," he continues to add "In my eyes this is a perfect match. From all what I have seen, Molecular Connections adheres to the same rigorous quality standards as Genomatix does," he concludes.
Mr. Jignesh Bhate, CEO of Molecular Connections remarked "We are happy to be associated with Genomatix. We believe NetPro™ will provide significant value to the existing and future users of BSPE."
Molecular Connections today announced the licensing of NetPro™, the completely hand-curated knowledgebase of protein interactions to GlaxoSmithKline.
The current version of NetPro™, Molecular Connections' proprietary protein interaction knowledgebase covers more than 100,000+ manually curated and annotated protein-protein interactions from published biomedical literature. Molecular Connections will issue subsequent updates to the database, on a regular basis. This new version of NetPro™ has more components of data in granular format for easy analysis in a high through-put manner.
All the interactions have been validated through expert curation by Molecular Connections' in-house scientific team. All molecules in NetPro™ are linked to public Ids (like LocusLink), facilitating ready integration of interactions information into proprietary databases. The protein-protein interactions in NetPro™ are complemented with annotations of the profiled proteins with scientific literature information on a variety of important subjects, including biological pathways/sub-pathways, Species, Experimental Technique, Diseases implicated etc.
Jignesh Bhate, CEO of Molecular Connections' said "NetPro™ is increasingly becoming a valued tool for various academic and commercial labs around the world studying interaction/pathways data for augmenting their systems biology initiatives. We are very pleased to be working with research and development led pharmaceutical companies such as GlaxoSmithKline."
Protein interactions play significant roles in various aspects of the structural and functional organization of the cell, and their elucidation sheds light on the molecular mechanisms of biological processes. Having a database of protein interactions will assist researchers to identify drugs that target pathways related to a specific disease while avoiding pathways associated with unwanted side effects and toxicity. Key to advancing knowledge of biochemical pathways and networks is the intelligent analysis and mining of available literature, which is a large untapped resource containing information about thousands of interactions.
Bangalore, India - Molecular Connections today announced the licensing of NetPro™, the completely, hand-curated knowledgebase of protein interactions to Dr. David Eisenberg's research Lab at DOE Institute for Genomics and Proteomics, UCLA.
NetPro™, Molecular Connections' proprietary protein interaction knowledgebase covers more than 30,000 expert curated and annotated protein-protein interactions from published biomedical literature. Molecular Connections will issue subsequent updates to the database, on a regular basis.
All the interactions have been validated through expert curation by Molecular Connections' in-house scientific team. All molecules in NetPro™ are linked to public Ids (like LocusLink), facilitating ready integration of interactions information into proprietary databases. The protein-protein interactions in NetPro™ are complemented with annotations of the profiled proteins with scientific literature information on a variety of important subjects, including Biological Pathways/sub-pathways, Species, Experimental Technique, Diseases implicated etc.
NetPro™ is increasingly becoming a critical input for various academic and commercial labs around the world studying interaction/pathways data for augmenting their systems biology initiatives.
Protein interactions play significant roles in various aspects of the structural and functional organization of the cell, and their elucidation sheds light on the molecular mechanisms of biological processes. Having a database of protein interactions will allow researchers to identify drugs that target pathways related to a specific disease while avoiding pathways associated with unwanted side effects and toxicity. Key to advancing our knowledge of biochemical pathways and networks is the intelligent analysis and mining of available literature, which is a large untapped resource containing information about thousands of interactions.
1. The partnering of structural and computation biology in the determination of folds for proteins in genomes, and the analysis of function and interactions from genome sequences.
2. The development of molecular nuclear medicine, including new diagnostic biological imaging procedures and their relationship to drug therapies to improve the quality of life.
For more information please visit www.doe-mbi.ucla.edu
LBRI licenses Molecular Connections' NetPro™: Database of Interacting Proteins
Bangalore, India - Molecular Connections today announced the licensing of its NetPro™ Database to Lion Bioscience Research Inc. (LBRI).
NetPro™, Molecular Connections' proprietary protein interaction database covers more than 30,000 expert curated and annotated protein-protein interactions. NetPro™ has been built using interaction data extracted with the company's proprietary information extraction engine, M-CHIPST. All the interactions are from peer reviewed published scientific literature and have been validated through manual cross-checking by Molecular Connections' in-house scientific team. Molecular Connections will issue subsequent updates to the database, which will include the latest advances recorded in scientific literature.
The NetPro™ database is organized in standard relational database format with built in front-end to effectively navigate and analyse the data. NetPro™ data is linked to public Ids (like LocusLink), facilitating integration of interactions information into proprietary drug discovery databases. The protein-protein interactions in NetPro™ are complemented with annotations of the profiled proteins with scientific literature information on a variety of important subjects, including -
* Cellular Localization
* Biological Pathways
* Species
* Experimental Technique
* Diseases implicated
* Gene Ontology
Anthony Caruso, President, Lion bioscience Research, Inc, mentioned "Protein interaction data are extremely valuable, but mostly only exists in the literature and not in well structured databases. The hand curated NetPro™ database provides a comprehensive and accurate account of known protein interactions, which will save us considerable time and money in our discovery efforts."
Protein interactions play significant roles in various aspects of the structural and functional organization of the cell, and their elucidation sheds light on the molecular mechanisms of biological processes. Having a database of protein interactions will allow researchers to identify drugs that target pathways related to a specific disease while avoiding pathways associated with unwanted side effects and toxicity. Key to advancing our knowledge of biochemical pathways and networks is the intelligent analysis and mining of available literature, which is a large untapped resource containing information about thousands of interactions.
"Protein-protein interactions are critical factors regulating the normal functions of cells and unraveling the interacting partners of a protein of interest is an invaluable way of understanding innate protein function" said Jignesh Bhate, Molecular Connections' Founder and Director. "Moreover, the ability to analyze a large network of interacting proteins, combined with gene expression data, will play a critical role in identifying and validating potential drug targets".
LION Bioscience Research Inc. was founded as a subsidiary of LION Bioscience to develop and apply information technology exclusively for the Bayer group.
LION bioscience (ISIN: DE0005043509, Reuters: LIOG, Bloomberg: LIO, Nasdaq: LEON) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. LION's performance software solutions developed by its scientific and IT experts enable researchers to simultaneously compile and analyze data across various phases of the R&D process. Research time and costs are reduced, as scientists are able to identify and focus on the most promising drug candidates earlier.
LION sets the standard for integration solutions with more than 280 corporate and academic customers globally including AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, Eli Lilly, GlaxoSmithKline, IBM, Incyte, Johnson&Johnson, Merck Inc., Nestlé, Novartis, Schering AG and Sumitomo Pharmaceuticals. LION's solutions include SRS for bioinformatics data access, iDEA pkEXPRESST with analysis and prediction tools for ADME/tox, LION Target EngineT for target identification and optimization, LION Lead EngineT for lead identification and optimization, LION DiscoveryCenterT for biological and chemical data and application integration and LION SolutionCenterT for Professional Services.
Except for the historical information contained herein, the matters set forth in this press release are forward looking within the meaning of the Private Securities Litigation Reform Act of 1995, and other applicable U.S. and German laws. These forward-looking statements may include projections, estimates, targets, goals and descriptions of future events. Such statements are based on the current targets that LION has set itself and on LION's current expectations, each of which is subject to risks and uncertainties. LION's actual results may vary materially from those targeted, expected or projected because of factors such as exchange rate fluctuations, uncertainties relating to technologies, product and solution development, acceptance by the market of LION's offerings, market or industry trends, success of LION's business model and strategy, competition, cost or pricing of LION's products and solutions, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, or patent or copyright protection and litigation. We refer you to LION's Annual Report on Form 20-F, as filed with the Securities and Exchange Commission (SEC) on June 18, 2002, as well as LION's future SEC filings, in which these and other risk factors are discussed. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained in this announcement, whether as a result of new information, change of assumptions or business model, future developments or otherwise. LION bioscienceR, Life Science InformaticsT, LION DiscoveryCenterT, LION SolutionCenterT, LION Hosted ServicesT, LION Target EngineT, LION Lead EngineT, LSIT, bioSCOUTR, arraySCOUTT, arrayTAGT, arrayBASET, genomeSCOUTT, pathSCOUTT, pSCOUTT and iDEAT are either registered trademarks of LION bioscience AG or its subsidiaries in the United States and/or other countries, or there are pending applications by LION bioscience AG or its subsidiaries for these trademarks in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademark of the respective owners.